A Randomised, Double-blind, Placebo-controlled Study, in COPD Patients With and Without a Confirmed Respiratory Virus Infection Assessing Anti-viral Biomarker Responses and Clinical Effects of Inhaled SNG001 Compared to Placebo

Status: Suspended

Phase of Trial: Phase II

Latest Information Update: 06 Feb 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interferon beta-1a (Primary)
Indications Chronic obstructive pulmonary disease
Focus Adverse reactions; Biomarker; Pharmacodynamics; Registrational; Therapeutic Use
Sponsors Synairgen

Most Recent Events

07 Sep 2022 According to an Synairgen media release, full results will be submitted for publication in a peer reviewed journal.
07 Sep 2022 Positive data from additional assessments presented in the Synairgen Media Release.
07 Dec 2021 Results published in the Synairgen Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight